Instituto do Câncer de São Paulo Octavio Frias de Oliveira é um centro de atendimento médico e hospitalar que funciona como autarquia vinculada ao Governo do Estado de São Paulo.

During the past decade, Instituto do Cancer do Estado de Sao Paulo - ICESP conducted 112 clinical trials. In the 10-year time frame, 112 clinical trials started and 34 clinical trials were completed, i.e. on average, 30.4% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 18 clinical trials were completed. i.e. 36% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto do Cancer do Estado de Sao Paulo - ICESP" #1 sponsor was "Instituto do Cancer do Estado de São Paulo" with 39 trials, followed by "Hoffmann-La Roche" with 37 trials sponsored, "Latin American Cooperative Oncology Group" with 8 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 7 trials sponsored and "University of Sao Paulo" with 7 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 38 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto do Cancer do Estado de Sao Paulo - ICESP" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Eli Lilly and Company" with 3 trials as a collaborator, "Fundação Faculdade de Medicina" with 3 trials as a collaborator and "Instituto do Cancer do Estado de São Paulo" with 3 trials as a collaborator. Other collaborators include 47 different institutions and companies that were collaborators in the rest 44 trials.

According to Clinical.Site data, the most researched conditions in "Instituto do Cancer do Estado de Sao Paulo - ICESP" are "Breast Cancer" (18 trials), "Non-Small Cell Lung Cancer" (6 trials), "Cancer" (5 trials), "Prostate Cancer" (5 trials) and "Cervical Cancer" (4 trials). Many other conditions were trialed in "Instituto do Cancer do Estado de Sao Paulo - ICESP" in a lesser frequency.

Most popular intervention types in "Instituto do Cancer do Estado de Sao Paulo - ICESP" are "Drug" (118 trials), "Other" (15 trials), "Procedure" (12 trials), "Radiation" (12 trials) and "Device" (6 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (20 trials), "Carboplatin" (14 trials), "Cisplatin" (14 trials), "Atezolizumab" (13 trials) and "Gemcitabine" (9 trials). Other intervention names were less common.

The vast majority of trials in "Instituto do Cancer do Estado de Sao Paulo - ICESP" are 119 trials for "All" genders, 21 trials for "Female" genders and 14 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto do Cancer do Estado de Sao Paulo - ICESP". 1 are not yet recruiting, 32 are recruiting, 35 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 57 completed trials in Instituto do Cancer do Estado de Sao Paulo - ICESP, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto do Cancer do Estado de Sao Paulo - ICESP, 2 "Phase 1" clinical trials were conducted, 54 "Phase 2" clinical trials and 69 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 18 trials that are defined as “Not Applicable".

Instituto do Cancer do Estado de Sao Paulo - ICESP has several departments that took part in Clinical trials: "Instituto do Câncer do Estado de São Paulo - ICESP, Núcleo de Pesquisa" - 2 trials, "Instituto do Câncer de São Paulo - ICESP" - 2 trials